Investors

2023

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, notes the announcement (14 June 2022) by ProBiotix Health plc (AQSE: PBX) ("ProBiotix Health"), that Steen Andersen ("Steen") has been appointed as Chief Executive Officer ("CEO"), and that Steen will join the company after completing his notice period with his current employer. The Company has a 44 per cent. shareholding in ProBiotix Health.

This is part of a long-planned strategy by OptiBiotix and its portfolio companies (the "Group") to appoint experienced industry commercial leaders to each part of the business allowing the Group CEO to focus on identifying, developing and acquiring the new technologies or companies that will provide the Group with a pipeline of products and applications to deliver future growth and market value. This structure gives shareholders exposure to multiple opportunities within the emerging microbiome space and affords the potential to deliver additional value through separate public listing of the businesses and dividend return as achieved with the listing of ProBiotix Health earlier in the year.

Stephen O'Hara, CEO of OptiBiotix, commented: "The appointment of Steen as CEO of ProBiotix Health will help accelerate the growth and recognition of the business into its next phase of evolution.  Having established international sales and brand awareness of its award winning LP_LDL® probiotic as an ingredient, ProBiotix Health is now investing in building a presence in the dairy industry, extending the range of applications for LP_LDL® into other areas of health, and increasing access to the USA and Asian markets."

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. 

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. 

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits.

This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

2022

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, notes the announcement (14 June 2022) by ProBiotix Health plc (AQSE: PBX) ("ProBiotix Health"), that Steen Andersen ("Steen") has been appointed as Chief Executive Officer ("CEO"), and that Steen will join the company after completing his notice period with his current employer. The Company has a 44 per cent. shareholding in ProBiotix Health.

This is part of a long-planned strategy by OptiBiotix and its portfolio companies (the "Group") to appoint experienced industry commercial leaders to each part of the business allowing the Group CEO to focus on identifying, developing and acquiring the new technologies or companies that will provide the Group with a pipeline of products and applications to deliver future growth and market value. This structure gives shareholders exposure to multiple opportunities within the emerging microbiome space and affords the potential to deliver additional value through separate public listing of the businesses and dividend return as achieved with the listing of ProBiotix Health earlier in the year.

Stephen O'Hara, CEO of OptiBiotix, commented: "The appointment of Steen as CEO of ProBiotix Health will help accelerate the growth and recognition of the business into its next phase of evolution.  Having established international sales and brand awareness of its award winning LP_LDL® probiotic as an ingredient, ProBiotix Health is now investing in building a presence in the dairy industry, extending the range of applications for LP_LDL® into other areas of health, and increasing access to the USA and Asian markets."

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. 

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. 

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits.

This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, notes the announcement (14 June 2022) by ProBiotix Health plc (AQSE: PBX) ("ProBiotix Health"), that Steen Andersen ("Steen") has been appointed as Chief Executive Officer ("CEO"), and that Steen will join the company after completing his notice period with his current employer. The Company has a 44 per cent. shareholding in ProBiotix Health.

This is part of a long-planned strategy by OptiBiotix and its portfolio companies (the "Group") to appoint experienced industry commercial leaders to each part of the business allowing the Group CEO to focus on identifying, developing and acquiring the new technologies or companies that will provide the Group with a pipeline of products and applications to deliver future growth and market value. This structure gives shareholders exposure to multiple opportunities within the emerging microbiome space and affords the potential to deliver additional value through separate public listing of the businesses and dividend return as achieved with the listing of ProBiotix Health earlier in the year.

Stephen O'Hara, CEO of OptiBiotix, commented: "The appointment of Steen as CEO of ProBiotix Health will help accelerate the growth and recognition of the business into its next phase of evolution.  Having established international sales and brand awareness of its award winning LP_LDL® probiotic as an ingredient, ProBiotix Health is now investing in building a presence in the dairy industry, extending the range of applications for LP_LDL® into other areas of health, and increasing access to the USA and Asian markets."

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. 

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. 

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits.

This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

2020

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, notes the announcement (14 June 2022) by ProBiotix Health plc (AQSE: PBX) ("ProBiotix Health"), that Steen Andersen ("Steen") has been appointed as Chief Executive Officer ("CEO"), and that Steen will join the company after completing his notice period with his current employer. The Company has a 44 per cent. shareholding in ProBiotix Health.

This is part of a long-planned strategy by OptiBiotix and its portfolio companies (the "Group") to appoint experienced industry commercial leaders to each part of the business allowing the Group CEO to focus on identifying, developing and acquiring the new technologies or companies that will provide the Group with a pipeline of products and applications to deliver future growth and market value. This structure gives shareholders exposure to multiple opportunities within the emerging microbiome space and affords the potential to deliver additional value through separate public listing of the businesses and dividend return as achieved with the listing of ProBiotix Health earlier in the year.

Stephen O'Hara, CEO of OptiBiotix, commented: "The appointment of Steen as CEO of ProBiotix Health will help accelerate the growth and recognition of the business into its next phase of evolution.  Having established international sales and brand awareness of its award winning LP_LDL® probiotic as an ingredient, ProBiotix Health is now investing in building a presence in the dairy industry, extending the range of applications for LP_LDL® into other areas of health, and increasing access to the USA and Asian markets."

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. 

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. 

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits.

This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

2019

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, notes the announcement (14 June 2022) by ProBiotix Health plc (AQSE: PBX) ("ProBiotix Health"), that Steen Andersen ("Steen") has been appointed as Chief Executive Officer ("CEO"), and that Steen will join the company after completing his notice period with his current employer. The Company has a 44 per cent. shareholding in ProBiotix Health.

This is part of a long-planned strategy by OptiBiotix and its portfolio companies (the "Group") to appoint experienced industry commercial leaders to each part of the business allowing the Group CEO to focus on identifying, developing and acquiring the new technologies or companies that will provide the Group with a pipeline of products and applications to deliver future growth and market value. This structure gives shareholders exposure to multiple opportunities within the emerging microbiome space and affords the potential to deliver additional value through separate public listing of the businesses and dividend return as achieved with the listing of ProBiotix Health earlier in the year.

Stephen O'Hara, CEO of OptiBiotix, commented: "The appointment of Steen as CEO of ProBiotix Health will help accelerate the growth and recognition of the business into its next phase of evolution.  Having established international sales and brand awareness of its award winning LP_LDL® probiotic as an ingredient, ProBiotix Health is now investing in building a presence in the dairy industry, extending the range of applications for LP_LDL® into other areas of health, and increasing access to the USA and Asian markets."

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. 

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. 

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits.

This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

2018

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, notes the announcement (14 June 2022) by ProBiotix Health plc (AQSE: PBX) ("ProBiotix Health"), that Steen Andersen ("Steen") has been appointed as Chief Executive Officer ("CEO"), and that Steen will join the company after completing his notice period with his current employer. The Company has a 44 per cent. shareholding in ProBiotix Health.

This is part of a long-planned strategy by OptiBiotix and its portfolio companies (the "Group") to appoint experienced industry commercial leaders to each part of the business allowing the Group CEO to focus on identifying, developing and acquiring the new technologies or companies that will provide the Group with a pipeline of products and applications to deliver future growth and market value. This structure gives shareholders exposure to multiple opportunities within the emerging microbiome space and affords the potential to deliver additional value through separate public listing of the businesses and dividend return as achieved with the listing of ProBiotix Health earlier in the year.

Stephen O'Hara, CEO of OptiBiotix, commented: "The appointment of Steen as CEO of ProBiotix Health will help accelerate the growth and recognition of the business into its next phase of evolution.  Having established international sales and brand awareness of its award winning LP_LDL® probiotic as an ingredient, ProBiotix Health is now investing in building a presence in the dairy industry, extending the range of applications for LP_LDL® into other areas of health, and increasing access to the USA and Asian markets."

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. 

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. 

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits.

This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.